WORKIVA
Workiva (NYSE:WK), provider of the world’s leading connected reporting and compliance platform, today announces that Netherlands-based NXP Semiconductors uses the Workiva platform to streamline filings with the U.S. Securities and Exchange Commission and to modernize its Sarbanes Oxley Act (SOX) processes.
“We use the Workiva platform to save time in our reporting processes and create efficiencies across our entire finance organization,” said Bryan Moiles, Assistant Corporate Controller at NXP. “We have teams in the Netherlands and the U.S., and the Workiva platform is the only solution that allows me to run a 24-hour clock where I don't have to worry about version control.”
With Workiva, Moiles and his team create automatic updates, track every change and seamlessly collaborate with colleagues around the world in real time to create trusted reports and regulatory filings.
“The Workiva platform is our one source of truth for all our reports,” said Moiles. “Because everything is linked together, we can turn things around a lot quicker if we get last-minute changes.”
With Workiva, NXP links their SOX risk-control matrix, process narratives and flowcharts and creates a streamlined workflow for team members and other approvers directly in their documents and reports. “Workiva makes it so easy to interact; our teams are more motivated to go in and get things done,” said Harris.
Moiles and his team plan to explore more uses for Workiva. In late 2019, NXP switched from filing as a Foreign Private Issuer to a U.S. domestic filer. "We have new documents to create. We still have to complete a statutory set of financial statements for local jurisdictions and we have new deadlines to meet,” said Moiles. “The Workiva platform is helping us achieve that timeline.”
“My ultimate goal is to make my department better business partners,” added Moiles. “I’m really excited about how we can grow our finance organization with Workiva.”
About Workiva
Workiva, the leading cloud provider of connected data, reporting and compliance solutions, is used by thousands of enterprises across 120 countries, including more than 75 percent of Fortune 500® companies, and by government agencies. Our customers have linked over five billion data elements to trust their data, reduce risk and save time. For more information about Workiva (NYSE:WK), please visit workiva.com .
Request a Workiva demo: www.workiva.com/request-demo
Read the Workiva blog: www.workiva.com/blog
Follow Workiva on LinkedIn: www.linkedin.com/company/workiva
Like Workiva on Facebook: www.facebook.com/workiva/
Follow Workiva on Twitter: www.twitter.com/Workiva
Claim not confirmed by FORTUNE or TIME INC. FORTUNE® and FORTUNE 500® are registered trademarks of Time Inc. and are used under license. FORTUNE and Time Inc. are not affiliated with, and do not endorse products or services of, Workiva Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005605/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution15.12.2025 14:05:00 CET | Press release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215843975/en/ With approximately 60% of oncology agents progressing from Phase I to Phase II, but only 3–6% reaching regulatory approval, the paper outlines the factors influencing early-stage success, including trial design, patient selection, and regional development pathways. The paper highlights Australia’s continued position as a global first-in-human (FIH) and early-phase research hub. Its ethics-led review frameworks, which can support trial initiation within roughly 4–8 weeks, combined with established FIH centers, oncology networks, and cost efficiencies, position Au
Ant Group Announces Major Upgrades to Its 15-Million-MAU AI Health App AQ Amid Wider Push into Health Sector15.12.2025 14:03:00 CET | Press release
Ant Group today announced major upgrades to its AI health app AQ, with a new Chinese name “Ant A-Fu.” The character “Fu” conveys good wishes and well-being, reflecting the app’s goal to promote better health and quality of life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215203213/en/ Ant Group’s AI health app AQ features three core capabilities: health Q&A, AI health companion, and integrated health services. The upgraded version of AQ now features three core capabilities: health Q&A, AI health companion, and integrated health services. Launched in June 2025, AQ has rapidly grown to 15 million monthly active users, making it China’s leading AI health management app. Positioned as an AI health companion service, AQ currently answers over 5 million health-related questions every day. The announcement comes amid China’s ongoing demographic shift. According to projections from the National Health Commission, by around 20
Copeland and Daikin Cooperation Brings Solutions to European Customers15.12.2025 14:00:00 CET | Press release
Strategic collaboration to bring innovative residential solutions designed to reduce emissions and enable sustainable home heating Copeland and Daikin, two global leaders in heating, ventilation and air conditioning (HVAC) solutions, today announced the expansion of their existing joint venture into Europe. Through this cooperation, the companies will introduce advanced inverter swing rotary compressors, power electronics and controls designed specifically for European residential heat pumps. This collaboration underscores both companies’ commitment to accelerate the energy transition, with heat pumps recognized by industry reports as a cornerstone technology helping to reduce global carbon dioxide emissions by an estimated 500 million tons by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215625806/en/ (Left to right) Ross B. Shuster, CEO of Copeland and Jiro Tomita, executive associate officer of Daikin As Europe
Visa Unveils New Global Stablecoins Advisory Practice15.12.2025 13:00:00 CET | Press release
Visa Consulting & Analytics combines advanced payments strategy and expert crypto knowledge to help clients innovate and grow with stablecoins technology Visa (NYSE: V), a global leader in digital payments, today announced the launch of its Stablecoins Advisory Practice. The new value-added service offering by Visa Consulting & Analytics (VCA) provides actionable insights and recommendations to guide banks, fintechs, merchants, and businesses of all sizes on market fit, strategy, and implementation. As the stablecoin market cap surpasses $250 billion, Visa’s settlement volume has accelerated, reaching a $3.5 billion annualized run rate as of November 30. Businesses are turning to Visa’s new Stablecoins Advisory Practice to unlock growth opportunities. “Putting our members first has always been our mission, and we’re committed to exploring innovations that strengthen financial health and convenience for those we serve. Stablecoins may represent an opportunity to enhance speed and lower
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom